BioVie Inc. Faces Multiple Class Action Lawsuits Over Clinical Trial Misconduct
Investors allege lack of oversight and significant non-compliance in BioVie's Phase 3 clinical trial, leading to a dramatic drop in stock prices.
Overview
- Class action lawsuits have been filed against BioVie Inc. for alleged securities fraud and other unlawful business practices.
- The lawsuits concern potential scientific misconduct and significant non-compliance with Good Clinical Practice (GCP) regulations in a Phase 3 clinical trial.
- BioVie's stock price plummeted following revelations of the misconduct, with significant drops on November 9 and November 29, 2023.
- Investors have until March 19, 2024, to seek appointment as Lead Plaintiff in the class action.
- Law firms Pomerantz LLP, Berger Montague, and Kirby McInerney LLP are representing investors in the lawsuits.